AbbVie Inc.
NYSE:ABBVDrug Manufacturers - General
-$4.65 today
- Market cap
- $505.47B
- Beta
- 0.31
- P/E (TTM)
- 105.6
- EPS (TTM)
- $2.05
- Dividend yield
- 3.11%
Volume 4.73M
Average 6.47M
ABBV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
AbbVie Inc.NYSE: ABBV
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA grows, but more slowly than its trailing trend
Q3 FY2026 EBITDA of $6.48B rose 84.4% year over year, behind the +88.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 24.7% from the prior quarter. Over 3 fiscal years it compounded at -10.0% a year.
Context
- EBITDA amounted to 28.8% of revenue in FY2025, up 2.4 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 19 analysts of $39.01B (+121.3%) for the fiscal year ending Dec 2026, a step up from the +18.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $6.48B-24.7% QoQ
- Last fiscal yearDec 2025
- $17.63B+18.2% YoY
- LTMSep 2026
- $24.15B+88.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +84.4% | +100.7% | +16.3 pp |
| 1 year | +18.2% | +121.3% | +103.0 pp |
| 3-year CAGR | -10.0% | +37.3% | +47.3 pp |
| 5-year CAGR | +23.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 17.63B USD
- Year-over-year change
- +18.2%
- 4-year CAGR
- -7.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.63B | +18.2% |
| FY2024 | 2024-12-31 | 14.91B | -13.2% |
| FY2023 | 2023-12-31 | 17.17B | -29.0% |
| FY2022 | 2022-12-31 | 24.17B | +1.0% |
| FY2021 | 2021-12-31 | 23.93B | — |
EBITDA vs competitors
How ABBV compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +88.7% is the 2nd highest of 10, against a peer median of +2.2%.
- EBITDA amounts to 36.6% of revenue for ABBV, versus a peer median of 34.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.3B USD | +103.7% | +54.1% | 54.4% | |
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Sep 2026 | $24.15B USD | +88.7% | -10.0% | 36.6% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B USD | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | $16.82B USD | +11.6% | -7.5% | 34.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| Peer median (excluding ABBV) | — | +2.2% | +11.6% | 34.2% | |
Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 56.2B | 58.05B | 54.32B | 56.33B | 61.16B |
| Cost of Revenue | 17.45B | 17.41B | 20.42B | 16.9B | 18.2B |
| Gross Profit | 38.75B | 40.64B | 33.9B | 39.43B | 42.96B |
| Gross Margin | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| Research & Development | 8.05B | 6.51B | 7.68B | 12.79B | 9.1B |
| Selling, General & Admin | 12.35B | 15.26B | 12.87B | 14.75B | 14.01B |
| Operating Expenses | 20.83B | 22.52B | 21.15B | 30.29B | 22.87B |
| Depreciation & Amortization | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
| EBITDA | 23.93B | 24.17B | 17.17B | 14.91B | 17.63B |
| EBITDA Margin | 42.6% | 41.6% | 31.6% | 26.5% | 28.8% |
| Operating Income | 17.92B | 18.12B | 12.76B | 9.14B | 20.09B |
| Operating Margin | 31.9% | 31.2% | 23.5% | 16.2% | 32.8% |
| Interest Income | 39M | 186M | 540M | 648M | 266M |
| Interest Expense | 2.42B | 2.23B | 2.22B | 2.81B | 2.89B |
| Other Income / Expenses | (4.94B) | (4.64B) | (6.51B) | (5.42B) | (13.49B) |
| Income Before Tax | 12.99B | 13.48B | 6.25B | 3.72B | 6.6B |
| Pre-Tax Margin | 23.1% | 23.2% | 11.5% | 6.6% | 10.8% |
| Income Tax Expense | 1.44B | 1.63B | 1.38B | (570M) | 2.36B |
| Net Income | 11.54B | 11.84B | 4.86B | 4.28B | 4.23B |
| Net Margin | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| EPS (Basic) | 6.48 | 6.65 | 2.73 | 2.40 | 2.37 |
| EPS (Diluted) | 6.45 | 6.63 | 2.72 | 2.39 | 2.37 |
| Weighted Avg Shares | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Weighted Avg Shares (Diluted) | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B |
AbbVie Inc.
NYSE:ABBV
Intrinsic Alpha fair value
Locked
Current Price
$285.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.